1. Clinical & Scientific Overview
Mirabegron (TIP-MED-000236, Reference Code [12.4]) is classified under
Urological & Renal Stone Medicines (Ch 12) as a Selective Beta-3 Adrenoceptor Agonist (Relaxes Detrusor Smooth Muscle During the Bladder Storage Phase to Increase Bladder Capacity Without Inhibiting Voiding Contractions).
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).
Representative Indian Market Examples (Edition 2.7 Ch 12 [12.4], p. 156): Mirbeg (Sun Pharma), Myrbetriq (Astellas), Bladmir (Intas), Mirago (Zydus), Megablast; In FDC with Solifenacin: Mirbeg-S, Bladmir-S — Strengths & Dosage Forms: Extended-Release (ER / PR) Film-Coated Tablets: 25 mg, 50 mg
Extended-Release (ER / PR) Film-Coated Tablets: 25 mg, 50 mg
3. Mechanism of Action & Pharmacodynamics
Selective Beta-3 Adrenoceptor Agonist (Relaxes Detrusor Smooth Muscle During the Bladder Storage Phase to Increase Bladder Capacity Without Inhibiting Voiding Contractions) acting on target receptor/enzyme pathways in Urological & Renal Stone Medicines (Ch 12): clinical efficacy is mediated via Selective Beta-3 Adrenoceptor Agonist (Relaxes Detrusor Smooth Muscle During the Bladder Storage Phase to Increase Bladder Capacity Without Inhibiting Voiding Contractions) for Overactive Bladder (OAB) with symptoms of urinary urgency, urinary frequency, and urge incontinence—preferred non-anticholinergic OAB agent in elderly patients, dementia patients on Donepezil, glaucoma patients, and men with BPH + OAB (alongside Tamsulosin)..
4. Therapeutic Indications & Evidence-Supported Uses
- Overactive Bladder (OAB) with symptoms of urinary urgency, urinary frequency, and urge incontinence—preferred non-anticholinergic OAB agent in elderly patients, dementia patients on Donepezil, glaucoma patients, and men with BPH + OAB (alongside Tamsulosin)
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: General Adult Reference: Initially 25 mg once daily (especially in elderly or mild-to-moderate renal/hepatic impairment); may increase to 50 mg once daily after 4–8 weeks based on efficacy and blood pressure. Follow urologist prescription.
Administration & Meal Timing: With or without food, swallowed whole with water—NEVER crush, chew, or divide the Extended-Release tablet! | Once daily in the morning.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal: Dosing depends on renal function! • eGFR 30–89 mL/min: 25 mg–50 mg OD (limit to 25 mg OD if taking strong CYP3A4 inhibitors). • eGFR 15–29 mL/min (Stage 4 CKD): Maximum dose is strictly 25 mg once daily! • eGFR <15 mL/min or Dialysis: Not recommended / avoid. Hepatic: Child-Pugh B (moderate): Max 25 mg once daily; Child-Pugh C (severe): Avoid.
Renal: Dosing depends on renal function! • eGFR 30–89 mL/min: 25 mg–50 mg OD (limit to 25 mg OD if taking strong CYP3A4 inhibitors). • eGFR 15–29 mL/min (Stage 4 CKD): Maximum dose is strictly 25 mg once daily! • eGFR <15 mL/min or Dialysis: Not recommended / avoid. Hepatic: Child-Pugh B (moderate): Max 25 mg once daily; Child-Pugh C (severe): Avoid.
Renal: Dosing depends on renal function! • eGFR 30–89 mL/min: 25 mg–50 mg OD (limit to 25 mg OD if taking strong CYP3A4 inhibitors). • eGFR 15–29 mL/min (Stage 4 CKD): Maximum dose is strictly 25 mg once daily! • eGFR <15 mL/min or Dialysis: Not recommended / avoid. Hepatic: Child-Pugh B (moderate): Max 25 mg once daily; Child-Pugh C (severe): Avoid.
7. Contraindications, Precautions & High-Risk Warnings
- STRICTLY CONTRAINDICATED in Severe Uncontrolled Hypertension (Systolic BP ≥180 mmHg and/or Diastolic BP ≥110 mmHg)! (Beta-3 and minor off-target cardiovascular sympathetic stimulation causes dose-dependent increases in blood pressure and resting heart rate!). Caution in bladder outlet obstruction or patients taking concurrent antimuscarinics.
Key Clinical Precautions: Renal: Dosing depends on renal function! • eGFR 30–89 mL/min: 25 mg–50 mg OD (limit to 25 mg OD if taking strong CYP3A4 inhibitors). • eGFR 15–29 mL/min (Stage 4 CKD): Maximum dose is strictly 25 mg once daily! • eGFR <15 mL/min or Dialysis: Not recommended / avoid. Hepatic: Child-Pugh B (moderate): Max 25 mg once daily; Child-Pugh C (severe): Avoid.
8. Adverse Effects Profile
- Blood pressure elevation / hypertension (7–11%), mild sinus tachycardia / palpitations, nasopharyngitis, urinary tract infection, headache. (Notably: Dry mouth and constipation rates are <2%, identical to placebo, and zero anticholinergic cognitive confusion!).
- Severe hypertensive surge in uncontrolled hypertensives, atrial fibrillation / tachycardia, urinary retention (rare, mainly if combined with solifenacin in unoperated BPH), angioedema.
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Moderate Inhibitor of CYP2D6 and P-glycoprotein: • Metoprolol, Carvedilol, Nebivolol, Propafenone, Flecainide, and Tricyclic Antidepressants (Amitriptyline/Nortriptyline): Mirabegron inhibits CYP2D6 and increases Metoprolol exposure by ~2- to 3-fold! • Digoxin: Mirabegron inhibits P-gp and increases Digoxin Cmax by 29%—monitor digoxin levels and pulse! • Warfarin: Monitor INR
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: 1. Explain that unlike older bladder tablets (like Solifenacin or Oxybutynin), Mirbeg / Mirago does NOT dry out the mouth, cause severe constipation, or cloud memory in senior citizens. 2. However, because it can nudge blood pressure upward, instruct hypertensive patients to check their blood pressure once a week during the first month and swallow the extended-release tablet whole without breaking it. 3. Full bladder control builds steadily over 4 to 8 weeks.
- Meal & Clock Timing Instruction: With or without food, swallowed whole with water—NEVER crush, chew, or divide the Extended-Release tablet! (Once daily in the morning.)
- Missed Dose Protocol: Take as soon as remembered unless within 12 hours of the next scheduled dose; never double.
- Geriatric Dispensing Pearl: The OAB drug of choice for elderly CGHS patients with cognitive impairment, dementia (safe with Donepezil!), constipation, or glaucoma—provided their blood pressure is controlled (<160/95 mmHg) and monitored!
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Extended-Release (ER / PR) Film-Coated Tablets: 25 mg, 50 mg
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 12 [12.4] (p. 156)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [12.10]-CMP159 Drotaverine Hydrochloride IP — Competitive Muscarinic (M2/M3) Receptor Antagonists & Direct Smoo
- [12.11]-C160 Disodium Hydrogen Citrate — Systemic & Urinary Alkalinisers / Urolithiasis Inhibitors
- [12.11]-CMP161 Phenazopyridine Hydrochloride IP — Systemic & Urinary Alkalinisers / Urolithiasis Inhibitors
- [12.12]-C162 Tadalafil — Selective Phosphodiesterase Type-5 (PDE5) Inhibitor (Pulmonary Va